Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The German etanercept registry for treatment of juvenile idiopathic arthritis.
Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, Hospach T, Huppertz HI, Keitzer R, Küster RM, Michels H, Moebius D, Rogalski B, Thon A; Paediatric Rheumatology Collaborative Group. Horneff G, et al. Among authors: huppertz hi. Ann Rheum Dis. 2004 Dec;63(12):1638-44. doi: 10.1136/ard.2003.014886. Epub 2004 Apr 28. Ann Rheum Dis. 2004. PMID: 15115709 Free PMC article. Review.
Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.
Horneff G, Ebert A, Fitter S, Minden K, Foeldvari I, Kümmerle-Deschner J, Thon A, Girschick HJ, Weller F, Huppertz HI. Horneff G, et al. Among authors: huppertz hi. Rheumatology (Oxford). 2009 Aug;48(8):916-9. doi: 10.1093/rheumatology/kep122. Epub 2009 May 29. Rheumatology (Oxford). 2009. PMID: 19483091 Clinical Trial.
Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.
Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, Dehoorne J, Panaviene V, Susic G, Stanevica V, Kobusinska K, Zuber Z, Mouy R, Rumba-Rozenfelde I, Breda L, Dolezalova P, Job-Deslandre C, Wulffraat N, Alvarez D, Zang C, Wajdula J, Woodworth D, Vlahos B, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). Horneff G, et al. Ann Rheum Dis. 2014 Jun;73(6):1114-22. doi: 10.1136/annrheumdis-2012-203046. Epub 2013 May 21. Ann Rheum Dis. 2014. PMID: 23696632 Free PMC article. Clinical Trial.
Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
Horneff G, Foeldvari I, Minden K, Trauzeddel R, Kümmerle-Deschner JB, Tenbrock K, Ganser G, Huppertz HI. Horneff G, et al. Among authors: huppertz hi. Arthritis Rheumatol. 2015 May;67(8):2240-9. doi: 10.1002/art.39145. Arthritis Rheumatol. 2015. PMID: 25891010 Clinical Trial.
[Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA's report regarding malignancies in anti-TNF-treated patients from Aug. 4, 2009].
Horneff G, Hospach T, Dannecker G, Föll D, Haas JP, Girschick HJ, Huppertz HI, Keitzer R, Laws HJ, Michels H, Minden K, Trauzeddel R. Horneff G, et al. Among authors: huppertz hi. Z Rheumatol. 2010 Aug;69(6):561-7. doi: 10.1007/s00393-009-0600-x. Z Rheumatol. 2010. PMID: 20174926 German.
Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.
Horneff G, Klein A, Klotsche J, Minden K, Huppertz HI, Weller-Heinemann F, Kuemmerle-Deschner J, Haas JP, Hospach A. Horneff G, et al. Among authors: huppertz hi. Arthritis Res Ther. 2016 Nov 24;18(1):272. doi: 10.1186/s13075-016-1170-3. Arthritis Res Ther. 2016. PMID: 27881144 Free PMC article.
195 results